Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies (NYSE: A) reported Q1 FY2025 results with revenue of $1.68 billion, showing growth of 1.4% reported and 1.2% core compared to Q1 2024. GAAP net income was $318 million ($1.11 per share), down from $348 million ($1.18 per share) in Q1 2024. Non-GAAP net income was $377 million ($1.31 per share), compared to $380 million ($1.29 per share) year-over-year.

By segment, Life Sciences and Diagnostics Markets Group revenue grew 4% reported to $647 million, Agilent CrossLab Group increased 1% to $696 million, while Applied Markets Group declined 4% to $338 million.

For FY2025, Agilent projects revenue of $6.68-6.76 billion (2.6-3.8% growth) and non-GAAP EPS of $5.54-5.61. Q2 outlook expects revenue of $1.61-1.65 billion with non-GAAP EPS of $1.25-1.28.

Agilent Technologies, listed on the NYSE under the ticker A, has declared a quarterly cash dividend of 24.8 cents per share of common stock.

The dividend will be paid on April 23, 2025, to all shareholders who are on record as of the close of business on April 1, 2025.

Future dividend amounts and their timing will be determined and approved by Agilent's board of directors.

Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following the Board of Directors meeting on February 6, 2025. The company will distribute a quarterly dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on March 7, 2025, to shareholders who are recorded as stockholders as of the close of business on February 24, 2025.

Agilent Technologies (NYSE: A) has announced it will release its first-quarter fiscal 2025 financial results after market close on Wednesday, February 26. The company will host a conference call at 1:30 p.m. PST to discuss the results. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website. A recording of the call will remain available on the website for 90 days.

Agilent Technologies (NYSE: A) will showcase new automated laboratory workflow solutions at SLAS2025 International Conference & Exhibition in San Diego from January 25-29. The company is focusing on advancing automation solutions to optimize lab performance, efficiency, and reproducibility across research, drug discovery, development, and manufacturing processes.

The automation solutions cover sample preparation, auto dilution, sample delivery, and washout across various applications including cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry. Key innovations to be showcased include the NovoCyte Opteon Spectral Flow Cytometer, SureSelect Cancer CGP Assay, ePrep Partnership for GC/MS and LC/MS analyses, and Avida for DNA sequencing.

The company will participate in a Solutions Spotlight Presentation on viral infectivity assays and a roundtable discussion about robotic automation in future laboratories. Agilent serves as a Diamond Sponsor of the event.

Agilent Technologies (NYSE: A) has awarded the Solutions Innovation Research Awards (SIRA) to Professors Anders Bentien, Walter Gössler, and Gregory Offer for their significant contributions to battery research.

Professor Bentien of Aarhus University will use the Agilent 5900 ICP-OES for his work on flow battery systems. Professor Gössler from the University of Graz will enhance lithium-ion battery recycling using the Agilent 8900 Triple Quadrupole ICP-MS. Professor Offer at Imperial College London will study lithium-ion battery degradation with the Agilent 5977C GC/MSD.

These awards aim to support innovative research in battery technology, focusing on new materials, recycling, and degradation processes. Agilent's initiative aligns with the need for sustainable energy solutions and aims to empower researchers with advanced analytical tools.

Agilent's SIRA program, established in 2023, supports university research in advanced materials and energy markets, providing state-of-the-art products and expertise to solve critical scientific problems.

Agilent Technologies (NYSE: A) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Padraig McDonnell and CFO Bob McMahon will deliver a presentation on Tuesday, January 14, 2025, at 9:45 a.m. Pacific time. Investors and interested parties can access both the live audio webcast and a replay of the presentation through the Agilent Investor Relations website.

Agilent Technologies (NYSE: A) has received Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx assay in Europe. The assay, which works exclusively with Agilent's Autostainer Link 48 staining solution, helps identify PD-L1 expression, a important biomarker for response to anti-PD-1 antibody therapies like OPDIVO® and OpdualagTM.

The certification covers nine cancer indications, including five companion diagnostic indications: non-small cell lung cancer, muscle invasive urothelial carcinoma, melanoma, esophageal squamous cell carcinoma, and gastric/gastroesophageal junction/esophageal adenocarcinoma. This certification ensures continued uninterrupted access for EU laboratories using Agilent's diagnostic products.

Agilent Technologies reported Q4 FY2024 results with revenue of $1.70 billion, up 0.8% reported but down 0.3% core year-over-year. Q4 GAAP EPS was $1.22, down 25%, while non-GAAP EPS reached $1.46, up 6%. For full FY2024, revenue declined 4.7% to $6.51 billion, with GAAP EPS of $4.43 (up 6%) and non-GAAP EPS of $5.29 (down 3%). The company projects FY2025 revenue between $6.79-6.87 billion, representing 4.3-5.5% growth, with non-GAAP EPS guidance of $5.54-5.61. Agilent also announced a new organizational structure aimed at becoming more customer-centric.